UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 182,661 Shares of DENTSPLY SIRONA Inc. $XRAY

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 28.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 452,599 shares of the medical instruments supplier’s stock after selling 182,661 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.23% of DENTSPLY SIRONA worth $4,802,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Eurizon Capital SGR S.p.A. bought a new position in DENTSPLY SIRONA during the fourth quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA in the 1st quarter worth about $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares during the last quarter. Performa Ltd US LLC boosted its stake in shares of DENTSPLY SIRONA by 116.1% during the 4th quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 2,283 shares during the period. Finally, Allworth Financial LP bought a new position in DENTSPLY SIRONA during the 2nd quarter valued at about $51,000. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Price Performance

DENTSPLY SIRONA stock opened at $10.72 on Thursday. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -3.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.84. The firm has a 50-day moving average of $12.18 and a two-hundred day moving average of $11.63. DENTSPLY SIRONA Inc. has a 1 year low of $9.40 and a 1 year high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. During the same period last year, the company posted $0.52 earnings per share. The company’s quarterly revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, research analysts forecast that DENTSPLY SIRONA Inc. will post 1.4 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Barclays raised their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research note on Monday, August 24th. Piper Sandler upped their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. BMO Capital Markets reiterated a “market perform” rating and issued a $13.00 price target on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Barrington Research set a $15.00 price objective on DENTSPLY SIRONA in a report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, DENTSPLY SIRONA currently has an average rating of “Hold” and an average price target of $13.54.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Brian McKeon bought 10,000 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was acquired at an average cost of $10.12 per share, with a total value of $101,200.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Brian Gladden bought 9,985 shares of the stock in a transaction on Monday, June 15th. The stock was purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. This trade represents a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.